SHANGHAI, December 7, 2023 -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, today announced the publication of abstracts reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the ESMO IMMUNO-ONCOLOGY Congress 2023 in Geneva, Switzerland, December 6-8, 2023. The details of the abstract is as follows:

Abstract #63TiP: A phase I study of tumor-infiltrating lymphocytes (TILs) in advanced solid tumors used an optimized regimen : MIZAR trial

Presentation Type: Trial in Progress (TiP) Poster

About MIZAR trial

MIZAR trial (GC101 TIL-ST-01, NCT05417750) is a phase 1, open label, nonrandomized, multicohort, multicenter study evaluating GC101 in patients with advanced solid tumors.

The NMPA allowed an Investigational New Drug (IND) Application to proceed in April 2022.

About Juncell Therapeutics

Juncell Therapeutics is a biotech dedicated to developing high-quality, accessible TIL cell therapies for the treatment of solid tumors. Juncell Therapeutics has established its proprietary DeepTIL® cell expansion and NovaGMP® gene modification technology platforms, which are designed to address the key challenges of conventional TIL therapies, making TILs "robust, competent, affordable, and accessible."

For more information, please visit:

https://www.juncell.com/en

https://www.linkedin.com/company/juncell-therapeutics

Juncell Contact:

contact@juncell.com